Consumer Health, Ninth Edition
References for Chapter 15
Cardiovascular Disease

  1. WHO publishes definitive atlas on global heart disease and stroke epidemic. World Health Organization news release, Sept 23, 2004.
  2. American Heart Association. Heart Disease and Stroke Statistics—2010 Update At-A-Glance. Dallas, 2010, The Association.
  3. Pearson TA and others. Markers of inflammation and cardiovascular disease application to clinical and public health practice. Circulation 107:499-511, 2003.
  4. He J and others. Passive smoking and the risk of coronary heart disease—A meta-analysis of epidemiologic studies. New England Journal of Medicine 340:920-926, 1999.
  5. Willett WC and others. Coffee consumption and coronary heart disease in women: A ten-year follow-up. JAMA 275:458-462, 1996.
  6. Triglycerides and heart disease. Harvard Heart Letter 11(1):1-5, 2000.
  7. Barrett S. Does lowering homocysteine prevent cardiovascular disease? Quackwatch Web site, June 26, 2010.
  8. Nusselder WJ and others. Living healthier for longer: Comparative effects of three heart-healthy behaviors on life expectancy with and without cardiovascular disease. BMC Public Health 9:487-495, 2009.
  9. Angermayr L and others. Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes mellitus—A systematic review of randomized controlled trials. Annals of Behavioral Medicine 40:49-64, 2010.
  10. Unal B and others. Life-years gained from modern cardiological treatments and population changes in England and Wales, 1981-2000. American Journal of Public Health 95:103-108, 2005.
  11. Castelli WP and others. Incidence of coronary heart disease and lipoprotein cholesterol levels—the Framingham Study. JAMA 256:2835-2838, 1986.
  12. Anderson KM and others. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA 257:2176-2180, 1987.
  13. Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA 263:1795-1801, 1990.
  14. Samuelson O and others. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. JAMA 258:1768-1776, 1987.
  15. Gotto AM Jr and others. The cholesterol facts :A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Dallas, 1990, American Heart Association.
  16. Lipid Clinics Research Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary artery disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:351-374, 1984.
  17. Danesh J and others. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102:1082-1085, 2000.
  18. Maher VM and others. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 274:1771-1774, 1995.
  19. Ridker PM and others. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 273:1269-1273, 1995.
  20. Grundy SM and others. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication No. 01-3670. Washington, D.C., 2001, Supt. of Documents.
  21. Grundy SM and others. Implications of recent clinical trials for the National Cholesterol Education Program Adult Panel III guidelines. Circulation 110:227-239, 2004.
  22. Lichtenstein AH. Trans fatty acids, plasma lipid levels, and risk of developing cardiovascular disease: A statement for health professionals. Circulation 95:2588-2590, 1997.
  23. Food labeling: Trans fatty acids in nutrition labeling; final rule. Federal Register 68:41433-41506, 2003.
  24. Rimm EB and others. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 275:447-451, 1996.
  25. Hu FB, Willet WC. Optimal diets for prevention of coronary heart disease. JAMA 288:2569-2578, 2002.
  26. Barnard RJ. Effects of life-style modification on serum lipids. Archives of Internal Medicine 151:1389-1394, 1991.
  27. Mirkin G, Rich D. Fat Free, Flavor Full. Boston, 1995, Little, Brown and Company.
  28. Newman B, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 275:55-60, 1996.
  29. Dalen JE, Dalton WS. Does lowering cholesterol cause cancer? JAMA 275:67-68, 1996.
  30. Lichtenstein AH and others. Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee. Circulation 114:82-96, 2006.
  31. Taubes G. Good Calories, Bad Calories: Fats, Carbs, and the Controversial Science of Diet and Health. New York, 2007, Anchor Books.
  32. Hall HA. Why we get fat. Science-Based Medicine Blog, Jan 18, 2011.
  33. USDA food composition data. USDA Nutrient Data Laboratory Web site, accessed May 23, 2005.
  34. Theuwissen E and others. Water-soluble dietary fibers and cardiovascular disease. Physiology and Behavior 94:285-292, 2008.
  35. Barrett S. Tips for lowering your dietary fat content. Quackwatch Web site, April 6, 2011.
  36. Kris-Etherton PM. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106:2747-2757, 2002.
  37. Omega-3 oil. Fish or pills? Consumer Reports 68(7):30-32, 2003.
  38. Cholesterol Treatment Trialists (TTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670-1681, 2010.
  39. Ornish D and others. Can lifestyle changes reverse coronary heart disease? Lancet 336:129-133, 1990.
  40. Gould KL, Ornish D and others. Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. American Journal of Cardiology 69:845-853, 1992.
  41. Gould KL, Ornish D and others. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 274:894-901, 1995.
  42. Ornish D and others. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 280:2001-2007, 1998.
  43. Esselstyn CB Jr. Updating a 12 -year experience with arrest and reversal therapy for coronary heart disease (an overdue requiem for palliative cardiology). American Journal of Cardiology 84:339-341, 1999
  44. Esselstyn CB Jr. Prevent and Reverse Heat Disease. New York, 2007, Penguin Group.
  45. Hall HA. Bill Clinton's diet. Science-Based Medicine Blog, Nov 23, 2011.
  46. Pritikin R. The New Pritikin Program: The Easy and Delicious Way to Shed Fat, Lower Your Cholesterol, and Stay Fit. New York, 1990, Simon & Schuster.
  47. Drugs for lipids. Treatment Guidelines from The Medical Letter 9:13-20, 2011.
  48. Hodes HN. Acute hepatic failure associated with the use of low-dose sustained-release niacin. JAMA 264:181, 1990.
  49. Henkin Y. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. JAMA 264:241-243, 1990.
  50. Etchason JA and others. Niacin-induced hepatitis: A potential side effect with low-dose time-release niacin. Mayo Clinic Proceedings 66:23-28, 1991.
  51. McKenney JM and others. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 271:672-677, 1994.
  52. Berger JS and others. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA 295:306-312, 2008.
  53. Hall HA. The International Network of Cholesterol Skeptics. Science-Based Medicine Blog, Feb 5, 2008.
  54. Ridker PM and others. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. New England Journal of Medicine 359:2195-2207, 2008.
  55. Alder R and others. A systematic review of the effectiveness of garlic as an anti-hyperlipidemic agent. Journal of the American Academy of Nurse Practitioners 15:120-123, 2003.
  56. Hennekens CH and others. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. New England Journal of Medicine 334:1145-1149, 1996.
  57. Vivekananthan DP and others. Use of antioxidant vitamins for the prevention of cardiovascular disease: Meta-analysis of randomized trials. Lancet 361:2017-2023, 2003.
  58. Coenzyme Q10. American Heart Association Web site, accessed March 23, 2011.
  59. Knuiman A and others. Lecithin intake and serum cholesterol. American Journal of Clinical Nutrition 49:266-268, 1989.
  60. Pharmanex v. Shalala, U.S. District Court for the District of Utah, March 30, 2001.
  61. Red yeast rice. Medical Letter 51:71-72, 2009.
  62. Brobst DE and others. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. Journal of Pharmacology and Experimental Therapeutics 310:528-535, 2004.
  63. Szapary PO and others. Guggulipid for the treatment of hypercholesterolemia: A randomized controlled trial. JAMA 290:765-772, 2003.
  64. Gaziano JM and others. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. New England Journal of Medicine 329:1829-1834, 1993.
  65. Friedman GD, Klatsky AL. Is alcohol good for your health? New England Journal of Medicine 329:1882-1883, 1993.
  66. Research news. University of Texas Southwestern Medical Center, Jan 2, 1997.
  67. Cholesterol-lowering margarines. The Medical Letter 41:56-58, 1999.
  68. FTC alleges Maryland companies lack support for claims that Heartbar is effective against cardiovascular diseases. FTC news release, June 12, 2003.
  69. FTC puts the squeeze on Tropicana’s orange juice claims. FTC news release, June 2, 2005.
  70. Reeves RA. Does this patient have hypertension? How to measure blood pressure. JAMA 273:1211-1218, 1995.
  71. Vesan RS and others. Residual lifetime risk for developing hypertension in middle-age women and men: The Framingham Heart Study. JAMA 287:103-110, 2002.
  72. Chobanian AV and others. JNC Express: Seventh Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md., 2004, National Institutes of Health.
  73. Chobanian AV and others. Seventh Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md., 2004, National Institutes of Health.
  74. Pescatello LS and others. American College of Sports Medicine position stand: Exercise and hypertension. Medicine & Science in Sports & Exercise 25:533-553, 2004.
  75. Appel LJ and others. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. New England Journal of Medicine 336:1117-1124, 1997.
  76. Sachs FM and others. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. New England Journal of Medicine 344:3-10, 2001.
  77. Aspirin and heart disease. American Heart Association Web site, March 3, 2011.
  78. Budoff MJ and others. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: A multicenter study. Circulation 93:898-904, 1996.
  79. O'Rourke RA and others. American College of Cardiology/American Heart Association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 102:126-140, 2000.

This page was revised on December 6, 2012.